91̽��

Plasma is a valuable source for diagnostics, providing insights into a patient’s health and disease status. Until recently, mass spectrometry-based plasma proteomics were limited to measuring only a few hundred proteins. However, advances in sample preparation and mass spectrometry instrumentation have significantly increased proteome coverage and throughput.

A breakthrough in plasma proteomics is the development of nanoparticle-based enrichment strategies for low-abundance proteins. Biognosys' P2 Plasma Enrichment technology enables the quantification of up to 7,000 proteins in plasma samples, offering high reproducibility, scalability, and cost-efficiency. These features make it suited for automation and the analysis of large cohort studies in biomarker discovery and precision medicine.

With the P2 technology implemented at PCF, combined with TimsTOF HT and the newly installed Orbitrap Astral MS-instrumentations, the facility can now better support researchers with high-quality data required for clinically relevant research.

"Proteomics is characterized by continuous innovation, and I am very pleased that we can now leverage from the latest technological advancements. We look forward to continuing to support researchers with this powerful platform and contribute to biomarker discovery and groundbreaking translational research. It is incredibly rewarding!” says Carina Sihlbom Wallem, unit manager at PCF, which is part of the national research infrastructure BioMS and Clinical MS within SciLifeLab. 

The new platform can quantify 5,000–7,000 proteins in plasma from diseased patients, compared to approximately 4,500 proteins in healthy controls, enabling deeper insights into disease biology. 

Access to the P2 Plasma Enrichment System enables PCF to better support researchers in understanding biological processes and disease mechanisms. With high-quality workflows for identifying biomarkers or multiprotein panels for various diseases such as cancer, cardiovascular diseases, and infections, the implications for precision medicine are significant.  

“Biognosis has proven to be a professional partner, and their implementation team has really made an effort to help us establish this workflow at PCF", says Carina Sihlbom Wallem.